Clinical trials: Digestive Disease
Pancreatic Cancer
A Study of Gemzar, Taxotere, and Xeloda for Adjuvant Pancreatic Cancer
The main purpose of this study will be to evaluate the toxicities as well as the efficacy of a chemotherapy regimen involving the combination of Gemzar, Taxotere, and Xeloda (GTX) in patients with pancreatic cancer, who have…
- Trial name
- NCT00882310
- Testing
- Gemcitabine, Docetaxel, Capecitabine
- Volunteers
- 37 people
- Sponsor
- Columbia University
Hepatic Encephalopathy
Safety and Tolerability Study of Rifaximin in Participants With a History of Hepatic Encephalopathy
This study will look at the safety of a drug used in participants who have had hepatic encephalopathy (HE) in the past.
- Trial name
- NCT00686920
- Testing
- Rifaximin
- Where
- 35 sites in United States, Canada
- Volunteers
- 322 people
- Sponsor
- Bausch Health Americas, Inc.
Advanced Gastric Cancer
Capecitabine and Cisplatin (XP)+Sorafenib in Advanced Gastric Cancer (AGC): Sorafenib+XP
There is strong scientific rationale for exploring the role of sorafenib with capecitabine and cisplatin (XP) in AGC. XP is a new standard of care in AGC and sorafenib is a novel signal transduction inhibitor that prevents tumor…
- Trial name
- NCT00565370
- Testing
- Capecitabine, Cisplatin, Sorafenib
- Where
- South Korea
- Volunteers
- 22 people
- Sponsor
- Asan Medical Center
Colorectal Cancer
A Study of Avastin (Bevacizumab) in Combination With XELOX in Patients With Metastatic Colorectal Cancer
This single arm study will assess the resection rate of liver metastasis, time to disease progression, and safety of neoadjuvant treatment with Avastin in combination with oxaliplatin and capecitabine (XELOX) in patients with…
- Trial name
- NCT00700570
- Testing
- bevacizumab [Avastin], capecitabine [Xeloda], oxaliplatin
- Where
- 6 sites in Taiwan
- Volunteers
- 45 people
- Sponsor
- Hoffmann-La Roche
Secondary Peritonitis
Treatment of Peritonitis in Automated Peritoneal Dialysis
The main infectious complication of peritoneal dialysis (PD) is bacterial peritonitis, which increases morbidity, mortality and conversion to hemodialysis. In Mexico, 485 patients per million people undergo PD.
- Trial name
- NCT04077996
- Testing
- Peritonitis treatment placed in APD, Peritonitis treatment with one exchange in CAPD
- Where
- 3 sites in Mexico
- Volunteers
- 64 people
- Sponsor
- Universidad de Colima
Infections, Intestinal
GSK2251052 in the Treatment of Complicated Intra-abdominal Infections
This study is being conducted to evaluate the safety, efficacy and pharmacokinetics/pharmacodynamics of GSK2251052 in subjects with complicated intra abdominal infections.
- Trial name
- NCT01381562
- Testing
- Drug: GSK2251052, Meropenem
- Where
- 31 sites in United States, Canada and 5 more
- Volunteers
- 15 people
- Sponsor
- GlaxoSmithKline
Nonalcoholic Fatty Liver Disease
The University of Michigan Wellness for Liver Health Study
The goal of this proposal is to pilot test our existing very-low carbohydrate diet intervention, adapted for adults with Non-alcoholic Fatty Liver Disease (NAFLD).
- Trial name
- NCT05010070
- Testing
- diet and lifestyle program
- Where
- United States
- Volunteers
- 11 people
- Sponsor
- University of Michigan
Exocrine Pancreatic Insufficiency (EPI)
A Study of Creon (Pancrelipase) in Resected and Non-resected Pancreatic Cancer Participants With Exocrine Pancreatic Insufficiency (EPI)
This is a study in participants with Exocrine Pancreatic Insufficiency (EPI) due to pancreatic cancer. This study will include resected participants who are post pancreatic cancer surgery, and an additional cohort in non-resected…
- Trial name
- NCT03859869
- Testing
- Pancrelipase
- Where
- 33 sites in United States
- Volunteers
- 1 people
- Sponsor
- AbbVie
Hepatocellular Carcinoma
Study of Bavituximab, Axitinib, and Avelumab in Advanced Hepatocellular Carcinoma
Across cancer types, immune checkpoint inhibitors have been shown to induce complete response, partial response, and stable disease after initial evidence of radiographic increase in tumor burden.
- Trial name
- NCT05249569
- Testing
- Axitinib, Avelumab, Bavituximab
- Where
- United States
- Volunteers
- 1 people
- Sponsor
- University of Texas Southwestern Medical Center
Opioid-Induced Constipation
Phase 2 Randomized, Double-Blind, Placebo-Controlled, Parallel Group Trial of Linaclotide Administered to Patients With Opioid-Induced Constipation Receiving Chronic Opioid Treatment for Non-Cancer Pain
The purpose of this study was to evaluate the safety and efficacy of linaclotide for the treatment of opioid-induced constipation (OIC), in adults receiving stable opioid treatment for chronic non-cancer pain that has been…
- Trial name
- NCT02270983
- Testing
- Linaclotide 145 micrograms, Linaclotide 290 micrograms
- Where
- 77 sites in United States
- Volunteers
- 254 people
- Sponsor
- Forest Laboratories
Nonalcoholic Steatohepatitis
Pentoxifylline in Patients With Nonalcoholic Steatohepatitis
One third of the population in the United States has nonalcoholic fatty liver disease (NAFLD). Nonalcoholic steatohepatitis (NASH), the progressive form of NAFLD, can lead to cirrhosis.Currently, there is no proven therapy for…
- Trial name
- NCT00590161
- Testing
- pentoxifylline (PTX)
- Where
- 3 sites in United States
- Volunteers
- 55 people
- Sponsor
- Case Western Reserve University
Hepatocellular Carcinoma
A Study of IMC-A12 in Combination With Sorafenib in Participants With Advanced Cancer of the Liver
To determine if IMC-A12 given in combination with Sorafenib is safe and effective for participants with advanced liver cancer.
- Trial name
- NCT00906373
- Testing
- IMC-A12 (cixutumumab) - 10 milligrams/kilogram (mg/kg), IMC-A12 (cixutumumab) - 20 mg/kg, Sorafenib
- Where
- 7 sites in United States
- Volunteers
- 47 people
- Sponsor
- Eli Lilly and Company
Primary Sclerosing Cholangitis
Primary Sclerosing Cholangitis With Oral Vancomycin by the Study of Its Antimicrobial and Immunomodulating Effects
Determine the benefit of oral vancomycin therapy for Primary Sclerosing Cholangitis.
- Trial name
- PSC (NCT01802073)
- Testing
- Oral Vancomycin
- Where
- United States
- Volunteers
- 34 people, healthy volunteers welcome
- Sponsor
- Stanford University
Head and Neck Cancer
Combination Chemotherapy and Radiation Therapy in Treating Patients With Locally Advanced Head and Neck Cancer
RATIONALE: Drugs used in chemotherapy, such as docetaxel, cisplatin, and fluorouracil, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing.
- Trial name
- NCT00352118
- Testing
- filgrastim, pegfilgrastim, cisplatin
- Where
- United States
- Volunteers
- 4 people
- Sponsor
- Masonic Cancer Center, University of Minnesota
Rectal Cancer
Study of High-Dose-Rate Endorectal Brachytherapy (HDRBT) in the Treatment of Locally Advanced Low Rectal Cancer
This research is being done to see how effective high-dose rate endorectal brachytherapy (HDRBT) is in treating cancer of the lowest part of the bowel (rectum).
- Trial name
- HDRBT (NCT01226979)
- Testing
- High-dose endorectal brachytherapy (HDRBT)
- Where
- United States
- Volunteers
- 16 people
- Sponsor
- Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Metastatic Colorectal Cancer, Colorectal Cancer
Morphotek Investigation in Colorectal Cancer: Research of MORAb-004 (MICRO)
The purpose of this study is to evaluate whether therapy with MORAb-004 is effective and safe in the treatment of metastatic, colorectal cancer.
- Trial name
- NCT01507545
- Testing
- MORAb-004, Best supportive care
- Where
- 67 sites in United States
- Volunteers
- 154 people
- Sponsor
- Morphotek
Head and Neck Neoplasms, Pheochromocytoma
A Broad Multi-histology Phase II Study of the Multi-Kinase Inhibitor R935788 (Fostamatinib Disodium) in Advanced Colorectal, Non-small Cell Lung, Head and Neck Hepatocellular and Renal Cell Carcinomas, and Pheochromocytoma and Thyroid Tumors (Multi-H...
Background: The drug R935788 (fostamatanib disodium) is a kinase inhibitor (i.e., it interferes with cell communication and growth and may prevent tumor growth).
- Conditions
- Head and Neck Neoplasms, Pheochromocytoma, Colorectal Neoplasms, Carcinoma, Non-Small-Cell Lung
- Trial name
- NCT00923481
- Testing
- Fostamatinib disodium
- Where
- United States
- Volunteers
- 37 people
- Sponsor
- National Cancer Institute (NCI)
Colorectal Neoplasms
Combination of Cetuximab, Capecitabine, and Oxaliplatin With or Without Bevacizumab
The purpose of this study is to determine the objective response rate of patients with previously untreated metastatic colorectal cancer treated with the combination of cetuximab, capecitabine, and oxaliplatin with out without…
- Trial name
- NCT00321100
- Testing
- bevacizumab, cetuximab, Oxaliplatin
- Where
- United States
- Volunteers
- 23 people
- Sponsor
- Fox Chase Cancer Center
Hepatitis C
Randomised Study of Interferon-free Treatment for Recently Acquired Hepatitis C in PWID and People With HIV Coinfection.
The aim of the study is to determine if treatment for recently acquired hepatitis C infection (with or without HIV coinfection) can be shortened when treating with the interferon-free therapy sofosbuvir/velpatasvir (SOF/VEL).
- Trial name
- REACT (NCT02625909)
- Testing
- SOF/VEL for 6 weeks, SOF/VEL for 12 weeks
- Where
- 25 sites in United States, Australia and 6 more
- Volunteers
- 222 people
- Sponsor
- Kirby Institute
Adult Giant Cell Glioblastoma, Adult Glioblastoma
18F-FPPRGD2 PET/CT or PET/MRI in Predicting Early Response in Patients With Cancer Receiving Anti-Angiogenesis Therapy
The purpose of the study is to conduct research of a new PET radiopharmaceutical in cancer patients. The uptake of the novel radiopharmaceutical 18F-FPPRGD2 will be assessed in study participants with glioblastoma multiforme…
- Conditions
- Adult Giant Cell Glioblastoma, Adult Glioblastoma, Adult Gliosarcoma, Male Breast Cancer
- Trial name
- NCT01806675
- Testing
- 18F-fludeoxyglucose (18F-FDG), 18F-FPPRGD2
- Where
- United States
- Volunteers
- 25 people
- Sponsor
- Sanjiv Sam Gambhir
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.